In addition, a DNA vaccination encoding prostatic acid phosphatase can result in the upregulation of PD-L1 expression on tumor cells of patients with castration-resistant but non-metastatic PCa, hence it provided an in-human rationale for the combination of DNA vaccines with PD-1 blockade for the treatment of PCa patients, which benefits much from vaccines but little from PD-1 antibodies as monotherapies (Rekoske et al., 2016). The gene discussed is ACP3; the disease is posterior cortical atrophy.